| Literature DB >> 30572851 |
Appiah-Korang Labi1,2, Noah Obeng-Nkrumah3, Gifty Sunkwa-Mills4,5, Antoinette Bediako-Bowan6,7,8, Christiana Akufo9, Stephanie Bjerrum4, Enid Owusu10, Christabel Enweronu-Laryea11, Japheth Awuletey Opintan5, Jorgen Anders Lindholm Kurtzhals1,12, Mercy Jemima Newman5.
Abstract
BACKGROUND: Excessive and inappropriate use of antibiotics in hospitalised patients contributes to the development and spread of antibiotic resistance. Implementing a stewardship programme to curb the problem requires information on antibiotic use. This study describes a multicentre point prevalence of antibiotic use among paediatric inpatients in Ghana.Entities:
Keywords: Antibiotic use; Children; Ghana; Paediatric; Point prevalence
Mesh:
Substances:
Year: 2018 PMID: 30572851 PMCID: PMC6302438 DOI: 10.1186/s12887-018-1367-5
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Prevalence of antibiotic use by age and across type of hospital
| Patient characteristics | Number of patients on | Prevalence of antibiotic use | ||
|---|---|---|---|---|
| Admission (%) | Antibiotics | Percent | 95% CI | |
| Age groupa | ||||
| ≤ 28 days | 208 (29.1) | 133 | 63.9 | 57.0–70.1 |
| > 28 days to ≤2 years | 152 (21.2) | 126 | 82.9 | 75.8–88.3 |
| > 2 years to ≤13 years | 272 (40.0) | 197 | 72.4 | 66.6–77.6 |
| > 13 years to ≤18 years | 84 (11.7) | 50 | 60.0 | 48.2–69.9 |
| Hospital type | ||||
| Tertiary | 340 (47.5) | 223 | 65.6 | 60.4–70.6 |
| Regional | 175 (24.4) | 146 | 83.4 | 77.2–88.2 |
| District | 201 (28.1) | 137 | 68.2 | 61.4–74.2 |
| Total | 716 (100.0) | 506 | 70.6 | 67.2–74.0 |
a≤28 days, neonates; > 28 days to ≤2 years, infants; > 2 years to ≤13 years, children; > 13 years to ≤18 years, adolescents; %, percentage, CI confidence interval
Fig. 1Number of antibiotics prescription per patients’age category across hospital type
Fig. 2Antibiotic use by ATC level 4 across hospital category. Others include nitrofurantoin and co-trimoxazole
Fig. 3Proportion of antibiotic use (ATC level 5) across patients’ age category
Indications for prescribing antimicrobial drugs (ATCa level 5) and the five most common antibiotics used
| Indication for antibiotic use | Top 5 antibiotic use among paediatric inpatients | ||||
|---|---|---|---|---|---|
| 1st | 2nd | 3rd | 4th | 5th | |
| All indications ( | Ceftriaxone ( | Gentamicin(n = 114, 13.7%) | Cefuroxime ( | Cloxacillin (n = 83, 9.9%) | Metronidazole (n = 82, 9.8%) |
| Community acquired infections (n = 508) | Ceftriaxone (n = 97, 19.1%) | Gentamicin (n = 85,16.7%) | Cefuroxime (n = 73, 14.4%) | Cloxacillin ( | Metronidazole ( |
| Hosptal acquired infections ( | Gentamicin (n = 12, 14.0%) | Cefuroxime (n = 8, 9.3%) | Ciprofloxacin(n = 7, 8.1%) | Amikacin (n = 6, 7.0%) | |
| Ampicillin | |||||
| Ceftriaxone | |||||
| Meropenem | |||||
| Medical prophylaxis | Ampicillin ( | Gentamicin ( | Cefotaxime ( | Amikacin (n = 14, 11.1%) | Crystal penicillin (n = 13, 10.3%) |
| Cloxacillin | |||||
| Surgical prophylaxis | Metronidazole (n = 20, 28.2%) | Amoxicillin-clavulanic acid (n = 15, 21.1%) | Cefuroxime (n = 13, 18.3%) | Ceftriaxone (n = 7,9.9%) | Ampicillin (n = 4, 5.6%) |
| Ciprofloxacin | |||||
| Unknown | Ceftriaxone (n = 8, 20.0%) | Amox-clavulanic acid (n = 4, 10.0%) | Metronidazole (n = 3, 7.5%) | Amikacin (n = 2, 5.0%) | Erythromycin (n = 1, 2.5%) |
| Ciprofloxacin | Cefuroxime | Azithromycin | |||
| Clindamycin | Crystal penicillin | Co-trimoxazole | |||
| Ampicillin | Amoxicillin | ||||
| Cloxacillin | |||||
| Gentamicin | |||||
aATC Anatomical Therapeutic Chemical Classification System
Anatomic sites of infection and the five most common antimicrobial drugs (ATC level 5) prescribed
| Anatomic sitesa | Top 5 antibiotic use (ATCa level 5) among paediatric patients | ||||
|---|---|---|---|---|---|
| 1st | 2nd | 3rd | 4th | 5th | |
| Resp | Gentamicin (n = 35, 17.9%) | Cefuroxime (n = 34, 17.3%) | Ceftriaxone (n = 29, 14.8%) | Amox-clav ( | Cloxacillin (n = 12, 6.1%) |
| C penicillin | |||||
| SSTBJ (n = 131) | Metronidazole (n = 24,18.3%) | Cloxacillin (n = 23, 17.6%) | Clindamycin (n = 20, 15.3%) | Cefuroxime (n = 19, 14.5%) | Amox-clav (n = 17, 13.0%) |
| GIT ( | Metronidazole (n = 29, 32.9%) | Cefuroxime (n = 17,19.3%) | Ciprofloxacin (n = 13,14.8%) | Ceftriaxone (n = 11,12.5%) | Gentamicin (n = 7, 8.0%) |
| GUOB (n = 33) | Metronidazole (n = 8,24.2%) | Amox-clav (n = 7, 21.2%) | Cefuroxime (n = 5, 15.2%) | Ceftriaxone (n = 4, 12.1%) | Ciprofloxacin (n = 3, 9.1%) |
| CNS | Amox-clava (n = 2, 7.7%) | Ceftriaxone (n = 11, 3.4%) | Cloxacillin (n = 5, 1.5%) | Metronidazole (n = 3,0.9%) | Gentamicin (n = 1, 0.3%) |
| Cefuroxime | Cefotaxime | ||||
| Meropenem | |||||
| UTI | Cefuroxime (n = 5, 35.7%) | Ciprofloxacin (n = 3, 21.4%) | Other drugsb ( | – | – |
| Other sites | Ceftriaxone (n = 4, 26.6%) | Amox-clav (n = 2, 13.1%) | Other drugsc (n = 4, 26.6%) | – | – |
| C penicillina | |||||
| UND (n = 328) | Gentamicin (n = 59,18.0%) | Ceftriaxone ( | Ampicillin (n = 45,13.7%) | Cloxacillin ( | Amikacin (n = 25,7.6%) |
aResp respiratory tract, GIT Gastrointestinal tract, UTI Urinary tract infection, CNS Central nervous system, SSTBJ skin, soft tissue, bones and joints, GUOB Genitourinary and obstetrics; Other sites comprise cardiovascular system and Ear, nose and throat; UND Undefined, Amox-clav Amoxicillin-clavulanic acid, C pencillin Crystal penicillin, ATC Anatomical Therapeutic Chemical Classification System
bother drugs include crystal penicillin (n = 1), ceftriaxone (n = 1), gentamicin (n = 1), meropenem (n = 1), nitrofurantoin (n = 1), erythromycin (n = 1)
cothers include crystal penicillin (n = 1), ceftriaxone (n = 1), gentamicin (n = 1), meropenem (n = 1), nitrofurantoin (n = 1), erythromycin (n = 1)